---
title: "RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286843768.md"
description: "RBC Capital has maintained a Hold rating on aTyr Pharma (ATYR) with a price target of $1.00, while the shares closed at $0.50. Analyst Brian Abrahams has an average return of 10.7% and a 52.10% success rate. Wells Fargo also issued a Hold rating, while Piper Sandler maintained a Buy rating on May 12."
datetime: "2026-05-19T01:46:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286843768.md)
  - [en](https://longbridge.com/en/news/286843768.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286843768.md)
---

# RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

In a report released on May 15, Brian Abrahams from RBC Capital maintained a Hold rating on aTyr Pharma, with a price target of $1.00. The company’s shares closed yesterday at $0.50.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Biogen. According to TipRanks, Abrahams has an average return of 10.7% and a 52.10% success rate on recommended stocks.

In addition to RBC Capital, aTyr Pharma also received a Hold from Wells Fargo’s Derek Archila in a report issued yesterday. However, on May 12, Piper Sandler maintained a Buy rating on aTyr Pharma (NASDAQ: ATYR).

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)